Signaling Lymphocytic Activation Molecule Family
"Signaling Lymphocytic Activation Molecule Family" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Type-I membrane glycoproteins that are expressed primarily on the surface of CD4 or CD8-positive T-CELLS; NATURAL KILLER CELLS; and some populations of B CELLS. They are characterized by an N-terminal, extracellular IMMUNOGLOBULIN-LIKE DOMAIN and a membrane-proximal IMMUNOGLOBULIN C2-SET DOMAIN. SLAMF receptors typically signal through homophilic interactions and are important for mediating the immune response and immune cell differentiation.
| Descriptor ID |
D000071176
|
| MeSH Number(s) |
D12.776.395.550.736 D12.776.543.550.746 D12.776.543.750.705.970
|
| Concept/Terms |
Signaling Lymphocytic Activation Molecule Family- Signaling Lymphocytic Activation Molecule Family
- Signaling Lymphocytic Activation Molecule Receptors
- SLAMF Receptors
- Signaling Lymphocytic Activation Molecule Family Receptors
- Signaling Lymphocytic Activation Molecules
- SLAM Family Receptors
|
Below are MeSH descriptors whose meaning is more general than "Signaling Lymphocytic Activation Molecule Family".
Below are MeSH descriptors whose meaning is more specific than "Signaling Lymphocytic Activation Molecule Family".
This graph shows the total number of publications written about "Signaling Lymphocytic Activation Molecule Family" by people in this website by year, and whether "Signaling Lymphocytic Activation Molecule Family" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Signaling Lymphocytic Activation Molecule Family" by people in Profiles.
-
Nilsen KE, Zhang B, Skjesol A, Ryan L, Vagle H, B?e MH, Orning P, Kim H, Bakke SS, Elamurugan K, Mestvedt IB, Stenvik J, Husebye H, Lien E, Espevik T, Yurchenko M. Peptide derived from SLAMF1 prevents TLR4-mediated inflammation in vitro and in vivo. Life Sci Alliance. 2023 12; 6(12).
-
Lu YJ, Barreira-Silva P, Boyce S, Powers J, Cavallo K, Behar SM. CD4 T?cell help prevents CD8 T?cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell Rep. 2021 09 14; 36(11):109696.
-
Forconi CS, Oduor CI, Oluoch PO, Ong'echa JM, M?nz C, Bailey JA, Moormann AM. A New Hope for CD56negCD16pos NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases. Front Cell Infect Microbiol. 2020; 10:162.
-
Friend R, Bhutani M, Voorhees PM, Usmani SZ. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma. Drug Des Devel Ther. 2017; 11:893-900.
-
Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010 Jun; 160(3):348-58.